Last mentioned: Mar 10, 2026
As GLP-1 receptor agonists like semaglutide and tirzepatide dominate the obesity market, the focus is shifting toward integrated nutritional strategies to mitigate muscle loss and gastrointestinal side effects. This evolution marks a transition from simple weight reduction to comprehensive body composition management.
This page surfaces every story mentioning GLP-1 Receptor Agonists across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where GLP-1 Receptor Agonists was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |